Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972023 · ClinicalTrials.gov registry record · Phase 1
DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00972023 is a Phase 1 study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 1 participants.
The verdict
NCT00972023, a Phase 1 study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Dehydroepiandrosterone (DHEA) may slow the growth of tumor cells and be an effective treatment for women with breast cancer. PURPOSE: This phase I trial is studying how well DHEA works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.
Interventions
- PROCEDURE Surgical resection
- DRUG DHEA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00972023
The ClinicalTrials.gov registry entry for NCT00972023 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgical resection is the first listed.
NCT00972023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00972023 about?
NCT00972023 is a clinical study titled "DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer". RATIONALE: Dehydroepiandrosterone (DHEA) may slow the growth of tumor cells and be an effective treatment for women with breast cancer. PURPOSE: This phase I trial is studying how well DHEA works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.
What is the current status of trial NCT00972023?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2010-02. Estimated completion is 2010-08-22.
What interventions are being tested in trial NCT00972023?
The interventions under investigation include: Surgical resection (PROCEDURE), DHEA (DRUG).
Who is sponsoring clinical trial NCT00972023?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.